☆ 4.4 Letter

Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis

HAEMATOLOGICA (2022)

Related references

Note: Only part of the references are listed.

Letter Hematology

Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

Maria Marcos-Jubilar et al.

Summary: In hospitalized COVID-19 patients with nonsevere pneumonia but elevated D-dimer, a short course of therapeutic-dose bemiparin does not appear to improve clinical outcomes compared to standard prophylactic doses.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Luis Ortega-Paz et al.

Summary: This study presents evidence from randomized controlled trials comparing different prophylactic anticoagulation regimens among hospitalized patients with COVID-19. The findings suggest that standard-dose prophylactic anticoagulation is more suitable than escalated-dose regimen, as it does not reduce all-cause death but increases the risk of major bleeding.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Michelle Sholzberg et al.

Summary: This study aimed to evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. The results of the study may help guide the treatment options for similar patients in the future.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19 The HEP-COVID Randomized Clinical Trial

Alex C. Spyropoulos et al.

Summary: Therapeutic-dose low-molecular-weight heparin reduces major thromboembolism and death in high-risk inpatients with COVID-19, with no significant effect observed in critically ill patients.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Renato D. Lopes et al.

Summary: In hospitalized COVID-19 patients with elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. Therapeutic-dose rivaroxaban and other direct oral anticoagulants should be avoided in these patients without an evidence-based indication for oral anticoagulation.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Patrick R. Lawler et al.

Summary: This study showed that therapeutic-dose anticoagulation with heparin in non-critically ill patients with Covid-19 increased the likelihood of survival to hospital discharge and reduced the need for cardiovascular or respiratory organ support compared to usual-care thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher et al.

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Hematology

Randomized trials of therapeutic heparin for COVID-19: A meta-analysis

Michelle Sholzberg et al.

Summary: Therapeutic heparin is beneficial in moderately ill patients with COVID-19, but not in severely ill patients.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Review Hematology

Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge

Francesco Violi et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Alex C. Spyropoulos et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Anna Cristina Bertoldi Lemos et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.